蛋白类与小分子激动剂对RXFP 1松弛素受体的差异激活
蛋白类与小分子激动剂对RXFP1松弛素受体的差异激活
作者: 小柯机器人 发布时间:2026/11/20 19:48:11
本期文章:《科学》:Volume 394 Issue 6826
Andrew C. Kruse研究团队在研究中取得进展。他们的研究开发出了蛋白和小分子激动剂对RXFP1松弛素受体的发散性激活。该研究于2026年11月19日发表于国际一流学术期刊《科学》杂志上。
松弛素受体RXFP1是一种G蛋白偶联受体(GPCR),属于富含亮氨酸重复序列的GPCR (LGR)亚家族。它的天然激动剂是松弛素-2,一种介导妊娠期心血管和肾脏适应的肽激素。RXFP1是治疗多种疾病的候选治疗靶点,包括各种形式的心力衰竭和纤维化。基于蛋白的松弛素-2类似物和小分子激动剂(AZD5462)都已进入2期临床试验,但这两种结构不同的分子如何激活受体尚不清楚。
附:英文原文
Title: Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists
Author: James Osei-Owusu, Tristan Girbau, Xunan Wang, Jeffrey S. Smith, Pengxiang Shen, Sarah C. Erlandson, Amanda K. Williamson, Xiaojing Cong, Mark W. Grinstaff, Daniel E. Kahne, Cherine Bechara, Andrew C. Kruse
Issue&Volume: 2026-11-19
Abstract: The relaxin receptor RXFP1 is a G protein–coupled receptor (GPCR) that belongs to the leucine-rich repeat–containing GPCR (LGR) subfamily. Its natural agonist is relaxin-2, a peptide hormone that mediates cardiovascular and renal adaptation in pregnancy. RXFP1 is a candidate therapeutic target for the treatment of several conditions, including various forms of heart failure and fibrosis. Both protein-based relaxin-2 analogs and a small-molecule agonist (AZD5462) have reached phase 2 clinical trials, yet how these two structurally divergent molecules activate the receptor is not known.
DOI: 10.1126/science.aei0135
Source: https://www.science.org/doi/10.1126/science.aei0135